Subscribe
Rituximab (Rituxan) is the most recent and the only treatment approved by the US Food and Drug Administration (FDA) for antineu­trophil cytoplasmic autoantibody (ANCA)-associated vasculitis, but there is still a role for cyclophosphamide in these diseases, especially in patients with more severe forms, according to several researchers. By Wayne Kuznar
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the joints and surrounding tissues. By Alice Goodman, Medical Writer
By Alice Goodman, Medical Writer Delayed-release prednisone (Rayos, Horizon Pharma) was approved by the US Food and Drug Administration (FDA) on July 26, 2012, for the treatment of a broad range of inflammatory-mediated diseases, including rheumatic, respiratory, dermatologic, allergic, endocrine, and hematologic diseases.
By Rosemary Frei, MSc A meta-analysis of studies of malignancies associated with tumor necrosis factor (TNF) inhibitors indicates the drugs are associated with a 45% increased risk for developing a nonmelanoma skin cancer but not with a significantly increased risk for lymphoma ...
By Wayne Kuznar Patients who initiate treatment with tumor necrosis factor (TNF) inhibitors for autoimmune diseases are not as likely to develop serious infections as those who start treatment with nonbiologic drugs, according to a study presented at the 2011 American College of Rheumatology meeting.
Page 2 of 2
Results 11 - 15 of 15
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology